MedTrace Logo

Treatment With Autologous Skeletal Myoblasts

NCT00975234 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 3

Last updated 2012-06-08

No results posted yet for this study

Summary

The purpose of this study is to determine the benefit of autologous skeletal myoblast injection in patients with old myocardial infarction and ventricular dysfunction versus conventional revascularisation therapy.

Conditions

  • Old Myocardial Infarction

Interventions

PROCEDURE

Intra-lesion injection of autologous skeletal myoblasts

Intra-lesion injection

PROCEDURE

Revascularisation

Revascularisation surgery

Sponsors & Collaborators

  • Fina Biotech

    collaborator UNKNOWN

  • Clinica Universidad de Navarra, Universidad de Navarra

    lead OTHER

Principal Investigators

  • Felipe Prósper, MD, PhD · Clinica Universidad de Navarra

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-05-31
Primary Completion
2010-01-31
Completion
2010-01-31

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00975234 on ClinicalTrials.gov